AbbVie Inc. - Methods for Treating HCV (EP3125889A1)
Summary
AbbVie Inc. filed European patent application EP3125889A1 for methods of treating Hepatitis C Virus (HCV) infection with pharmaceutical compositions classified under A61K 31/454, A61K 31/498, and A61K 31/7072. The European Patent Office published the application on April 15, 2026, establishing a priority date of October 16, 2015. The patent designates all European Patent Convention contracting states, covering AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.
What changed
The European Patent Office published AbbVie Inc.'s European patent application EP3125889A1 for HCV treatment methods, establishing a priority date of October 16, 2015. The application covers pharmaceutical compositions comprising heterocyclic compounds and nucleoside derivatives for antiviral treatment.
Competitors developing HCV therapies should monitor this filing during the nine-month opposition period following publication. Freedom-to-operate analyses for HCV compounds may need to account for AbbVie's claimed compositions and treatment protocols.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR TREATING HCV
Publication EP3125889A1 Kind: A1 Apr 15, 2026
Applicants
AbbVie Inc.
Inventors
BERNSTEIN, Barry M., DUTTA, Sandeep, LIU, Wei, PODSADECKI, Thomas J., CAMPBELL, Andrew L., MENON, Rajeev M., LIN, Chih-Wei, WANG, Tianli, AWNI, Walid M., MENSING, Sven
IPC Classifications
A61K 31/454 20060101AFI20151016BHEP A61K 31/498 20060101ALI20151016BHEP A61K 31/7072 20060101ALI20151016BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.